No Data
Boyuan Co., Ltd.: 2024 Annual Report Summary
Boyuan Co., Ltd.: Report for the first quarter of 2025
Boyuan Co., Ltd.: 2024 Annual Report
Boyuan Co., Ltd. (301617.SZ): The net income for 2024 is 0.213 billion yuan, an increase of 17.04% year-on-year.
Gelonghui April 24丨Boyuan Co., Ltd. (301617.SZ) announced its 2024 annual report, marking a milestone year in the company's development history. The company successfully listed on the GEM of the Shenzhen Stock Exchange on December 11, 2024. The company always adheres to a customer-centric approach, achieving steady improvement in operational performance, with key operational indicators continuing to grow compared to 2023. In 2024, revenue reached 1.328 billion yuan, an increase of 29.53% over the previous year. In 2024, the company continued to strengthen its market development efforts, further increasing the revenue scale of its main product series.
Boyuan Co., Ltd. (301617.SZ): The proportion of export Business revenue to total revenue is relatively low.
On April 14, Gelonghui reported that Boyuan Co., Ltd. (301617.SZ) stated on the interactive platform that, so far, the company's export business revenue accounts for a relatively low proportion of revenue.
Insufficient Growth At Shandong Boyuan Pharmaceutical & Chemical Co., Ltd. (SZSE:301617) Hampers Share Price
